Alza’s fentanyl TTS patch
Executive Summary
Received intensive final stage FDA review at "NDA Day" held July 30. Reportedly, the narcotic analgesic patch is expected to be approved within weeks. The NDA, filed in December 1987, has been under the purview of FDA's Pilot Drug Evaluation staff ("The Pink Sheet" May 21, T&G-4). TTS-fentanyl is designed for patients with severe, long-term pain often associated with cancer or for patients with acute postoperative pain. Janssen will market the novel dosage form in the U.S. and other countries. Alza has the right to co-promote TTS-fentanyl to U.S. oncologists.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.